InMode(US:INMD) Prnewswireยท2025-05-28 12:30Core Viewpoint - InMode Ltd. addresses concerns raised by DOMA Perpetual Capital Management regarding its operations, buyback strategy, and management performance, emphasizing its commitment to shareholder value and operational integrity [2][3][5][6]. Buyback Strategy - InMode has executed a share buyback program amounting to $412 million over the last 12 months and $508 million over the past 2.5 years, aiming to return capital to shareholders in a tax-efficient manner [3]. Manufacturing and Supply Chain - The company maintains that its manufacturing operations in Israel are essential due to the proximity to engineering, R&D, and logistics teams, and has successfully delivered products to 90 countries despite ongoing regional conflicts [4]. Sales Performance - The slowdown in North American sales is attributed to macroeconomic factors and financing challenges rather than issues within the sales management team, which is fully staffed and operating professionally [5]. Management Performance - The CEO refutes claims of poor leadership and emphasizes a lean management style, asserting that the Board of Directors will ultimately decide on his performance [6]. Company Overview - InMode is a global provider of innovative medical technologies, specializing in devices that utilize radio frequency technology for various medical fields, including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology [8].